Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

Recent findings in the animal model for multiple sclerosis (MS), experimental autoimmune encephalomyelitis, implicate a novel CD4+ T-cell subset (TH17), characterized by the secretion of interleukin-17 (IL-17), in disease pathogenesis. To elucidate its role in MS, brain tissues from patients with MS were compared to controls. We detected expression of IL-17 mRNA (by in situ hybridization) and protein (by immunohistochemistry) in perivascular lymphocytes as well as in astrocytes and oligodendrocytes located in the active areas of MS lesions. Further, we found a significant increase in the number of IL-17+ T cells in active rather than inactive areas of MS lesions. Specifically, double immunofluorescence showed that IL-17 immunoreactivity was detected in 79% of T cells in acute lesions, 73% in active areas of chronic active lesions, but in only 17% of those in inactive lesions and 7% in lymph node control tissue. CD8+, as well as CD4+, T cells were equally immunostained for IL-17 in MS tissues. Interestingly, and in contrast to lymph node T cells, no perivascular T cells showed FoxP3 expression, a marker of regulatory T cells, at any stage of MS lesions. These observations suggest an enrichment of both IL-17+CD4+ and CD8+ T cells in active MS lesions as well as an important role for IL-17 in MS pathogenesis, with some remarkable differences from the experimental autoimmune encephalomyelitis model.

[1]  Nathalie Arbour,et al.  Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation , 2007, Nature Medicine.

[2]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[3]  Hilde Cheroutre,et al.  Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid , 2007, Science.

[4]  D. Jarrossay,et al.  Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells , 2007, Nature Immunology.

[5]  R. Nussenblatt,et al.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 , 2007, Nature Medicine.

[6]  R. Locksley,et al.  IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge , 2007, Nature Immunology.

[7]  V. Kuchroo,et al.  Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation , 2007, Nature Medicine.

[8]  L. Hennighausen,et al.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. , 2007, Immunity.

[9]  C. Farina,et al.  Astrocytes are active players in cerebral innate immunity. , 2007, Trends in immunology.

[10]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[11]  Guang-Xian Zhang,et al.  Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. , 2007, Brain : a journal of neurology.

[12]  F. Powrie,et al.  Interleukin-23 drives innate and T cell–mediated intestinal inflammation , 2006, The Journal of experimental medicine.

[13]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[14]  X. Montalban,et al.  The value of animal models for drug development in multiple sclerosis. , 2006, Brain : a journal of neurology.

[15]  K. Mills,et al.  A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis , 2006, The Journal of experimental medicine.

[16]  S. Nakae,et al.  IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[17]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[18]  L. Presta,et al.  Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. , 2006, The Journal of clinical investigation.

[19]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[20]  R. Wu,et al.  Up-Regulation of CC Chemokine Ligand 20 Expression in Human Airway Epithelium by IL-17 through a JAK-Independent but MEK/NF-κB-Dependent Signaling Pathway1 , 2005, The Journal of Immunology.

[21]  M. Rovaris,et al.  Immunological patterns identifying disease course and evolution in multiple sclerosis patients , 2005, Journal of Neuroimmunology.

[22]  L. Fugger,et al.  Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? , 2005, Brain : a journal of neurology.

[23]  E. Coccia,et al.  Astrocytes Produce Dendritic Cell-Attracting Chemokines In Vitro and in Multiple Sclerosis Lesions , 2005, Journal of neuropathology and experimental neurology.

[24]  F. Mihara,et al.  Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. , 2005, Brain : a journal of neurology.

[25]  Ho‐Youn Kim,et al.  Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. , 2005, Molecules and cells.

[26]  M. Goldman,et al.  IL‐23 up‐regulates IL‐10 and induces IL‐17 synthesis by polyclonally activated naive T cells in human , 2005, European journal of immunology.

[27]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[28]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[29]  S. Nakae,et al.  Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice 1 , 2003, The Journal of Immunology.

[30]  Stephen G Waxman,et al.  Temporal Course of Upregulation of Nav1.8 in Purkinje Neurons Parallels the Progression of Clinical Deficit in Experimental Allergic Encephalomyelitis , 2003, Journal of neuropathology and experimental neurology.

[31]  R. Ravid,et al.  Cytokine, chemokine and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuli , 2003, Glia.

[32]  S. McColl,et al.  A Role for Macrophage Inflammatory Protein-3α/CC Chemokine Ligand 20 in Immune Priming During T Cell-Mediated Inflammation of the Central Nervous System1 , 2003, The Journal of Immunology.

[33]  B. Vainer,et al.  Upregulation of Interleukin-12 and -17 in Active Inflammatory Bowel Disease , 2003, Scandinavian journal of gastroenterology.

[34]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[35]  W. Brück,et al.  Interleukin-6 expression in human multiple sclerosis lesions , 2000, Neuroscience Letters.

[36]  W. Brück,et al.  Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology , 2000, Glia.

[37]  T. Martin,et al.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.

[38]  P. Kivisäkk,et al.  Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis , 1999, Multiple sclerosis.

[39]  M. Esiri,et al.  The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. , 1997, Brain : a journal of neurology.

[40]  M. Esiri,et al.  Oligodendrocyte reactions and cell proliferation markers in human demyelinating diseases , 1994, Neuropathology and applied neurobiology.

[41]  M. Cuzner,et al.  Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. , 1993, Cytokine.

[42]  H. Weiner,et al.  Immunohistochemical analysis of suppressor-inducer and helper-inducer T cells in multiple sclerosis brain tissue , 1987, Journal of Neuroimmunology.

[43]  M. Cuzner,et al.  Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis Possible role for microglia in lesion growth , 1986, Journal of the Neurological Sciences.

[44]  H. Weiner,et al.  Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions , 1986, Annals of neurology.

[45]  M. Esiri,et al.  Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis , 1983, Journal of the Neurological Sciences.

[46]  E. Reinherz,et al.  Multiple sclerosis: distribution of T cell subsets within active chronic lesions. , 1983, Science.

[47]  S. Mörk,et al.  IN‐SITU CHARACTERIZATION OF MONONUCLEAR CELL INFILTRATES IN LESIONS OF MULTIPLE SCLEROSIS , 1982, Neuropathology and applied neurobiology.

[48]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.

[49]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.

[50]  L. Steinman,et al.  The T lymphocyte in experimental allergic encephalomyelitis. , 1990, Annual review of immunology.

[51]  J. Mussini,et al.  [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.